NYSE:ALife Sciences
Agilent Technologies (A) Valuation Check After New Cell Imaging And Cancer Diagnostic Milestones
Agilent Technologies (A) has just added two fresh product milestones: the BioTek Cytation 9 cell imaging multimode reader and an FDA cleared PD-L1 IHC 22C3 companion diagnostic, giving investors new context for thinking about the stock.
See our latest analysis for Agilent Technologies.
These product launches and the recent dividend announcement come against a mixed backdrop, with a 7 day share price return of 4.75%, a 90 day share price return of 16.29%, and a 3 year total shareholder return...